Combination of Metformin With Gefitinib to Treat NSCLC
A Phase II, Randomized, Placebo Controlled Study to Evaluate the Efficacy of the Combination of Gefitinib and Metformin in Patients With Locally Advanced and Metastatic Non-Small-Cell-Lung-Cancer
Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
A PHASE2 clinical study on Advanced Cancer and EGFR Gene Amplification, this trial is completed. The trial is conducted by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University and has accumulated 7 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jul 2018 — Jan 2021 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Jun 2018 — Jul 2018 [monthly]
Unknown Status PHASE2
▶ Show 2 earlier versions
-
Feb 2018 — Jun 2018 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jan 2017 — Feb 2018 [monthly]
Active Not Recruiting PHASE2
First recorded
May 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Chongqing, China